CA

Bombardier Transportation appoints Rajeev Joisar as Managing Director for India

Friday, July 10, 2020 - 7:00am

BERLIN, July 10, 2020 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/06acfd21-a8d9-407e-9...

Key Points: 
  • BERLIN, July 10, 2020 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/06acfd21-a8d9-407e-9...
    Global mobility technology leader Bombardier Transportation announced today the appointment of Rajeev Joisar as Managing Director for India.
  • For almost two decades, Rajeev Joisar has been a trusted leader and proven business partner for Bombardier and our customers in India, and he is a great addition to our senior team, said Andrew DeLeone, President of the Europe, Middle East, Africa and India region at Bombardier Transportation.
  • As the Managing Director for India, Rajeev will nurture and further develop our valuable customer relationships, while growing a sustainable business in India, he added.
  • Rajeev Joisar has held various roles with increasing responsibility during his career at Bombardier, and he brings vast experience in managing complex multi-site cross-divisional projects.

MHK Long -Term Investor Alert: Johnson Fistel Continues to Investigate Mohawk Industries; Should Management be Held Accountable for Investors Losses?

Friday, July 10, 2020 - 5:52am

SAN DIEGO, July 10, 2020 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Mohawk Industries, Inc. ("Mohawk" or the "Company") (NYSE: MHK) against certain of its officers and directors.

Key Points: 
  • SAN DIEGO, July 10, 2020 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Mohawk Industries, Inc. ("Mohawk" or the "Company") (NYSE: MHK) against certain of its officers and directors.
  • You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.
  • If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ( jimb@johnsonfistel.com ) at 619-814-4471.
  • Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia.

Nkarta Announces Pricing of Initial Public Offering

Friday, July 10, 2020 - 5:44am

SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share.
  • Nkarta anticipates total gross proceeds of approximately $252.0 million, before deducting underwriting discounts and commissions and other offering expenses.
  • The offering is expected to close on or about July 14, 2020, subject to customary closing conditions.
  • In addition, Nkarta has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the initial public offering price.

Aurora Spine Corporation Files Condensed Consolidated Financial Statements for the Three Months Ended March 31, 2020

Friday, July 10, 2020 - 1:47am

CARLSBAD, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (Aurora Spine or the Company) (TSXV: ASG) announces financial results for the First Quarter 2020, ended March 31, 2020.

Key Points: 
  • CARLSBAD, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (Aurora Spine or the Company) (TSXV: ASG) announces financial results for the First Quarter 2020, ended March 31, 2020.
  • Q1 2020 started strongly for the Company based on several financial metrics and reflects significant research and development efforts.
  • However, it was affected significantly by COVID-19 due to the suspension of elective surgeries in the United States in March 2020.
  • The Financial Statements together with the Management Discussion and Analysis can be found on SEDAR at www.sedar.com.

NovaGold Investors: Company Investigated by the Portnoy Law Firm

Friday, July 10, 2020 - 1:27am

LOS ANGELES, July 09, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NovaGold Resources Inc. ("NovaGold" or the "Company") (NYSE: NG) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Key Points: 
  • LOS ANGELES, July 09, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NovaGold Resources Inc. ("NovaGold" or the "Company") (NYSE: NG) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • Investors are encouraged to contact attorney Lesley F. Portnoy ,by phone 310-692-8883 or email : lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

J2 Global Investors: Lawsuit Filed To Recover Losses Suffered, Contact the Portnoy Law Firm to File a Claim  

Friday, July 10, 2020 - 1:03am

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • If you suffered a loss you have untilSeptember 8, 2020to request that the Court appoint you as lead plaintiff.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

AXT, Inc. Schedules Second Quarter 2020 Earnings Release for July 22, 2020

Friday, July 10, 2020 - 2:00am

FREMONT, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- AXT, Inc. (NasdaqGS: AXTI ), a leading manufacturer of compound semiconductor substrates, will announce its financial results for the second quarter 2020 in a press release immediately following the close of market on July 22, 2020.

Key Points: 
  • FREMONT, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- AXT, Inc. (NasdaqGS: AXTI ), a leading manufacturer of compound semiconductor substrates, will announce its financial results for the second quarter 2020 in a press release immediately following the close of market on July 22, 2020.
  • The company will also host a conference call to discuss these results on July 22, 2020 at 1:30 p.m. PT.
  • Replays will be available at (855) 859-2056 (passcode 2378158) until July 28, 2020.
  • Additional investor information can be accessed at http://www.axt.com or by calling the companys Investor Relations Department at (510) 438-4700.

Pretivm Provides Notice of Second Quarter 2020 Operational and Financial Results Release Date and Conference Call Details

Friday, July 10, 2020 - 12:36am

VANCOUVER, British Columbia, July 09, 2020 (GLOBE NEWSWIRE) -- Pretium Resources Inc. (TSX/NYSE:PVG) (Pretivm or the Company) will release second quarter 2020 operational and financial results after market close on Wednesday, August 5th, 2020.

Key Points: 
  • VANCOUVER, British Columbia, July 09, 2020 (GLOBE NEWSWIRE) -- Pretium Resources Inc. (TSX/NYSE:PVG) (Pretivm or the Company) will release second quarter 2020 operational and financial results after market close on Wednesday, August 5th, 2020.
  • The webcast and conference call to discuss Q2 2020 will take place Thursday, August 6th, 2020 at 8:30 am PDT (11:30 am EDT) and can be accessed at www.pretivm.com .
  • Second quarter 2020 webcast and conference call details:

Bionano Genomics Solidifies its Entry into Solid Tumor Analysis with Launch of New Kit and Protocol that Significantly Simplify Tissue and Solid Tumor Analysis

Friday, July 10, 2020 - 12:30am

The kit has been designed to simplify isolation of Ultra High Molecular Weight (UHMW) DNA from a variety of solid tumors and tissue types.

Key Points: 
  • The kit has been designed to simplify isolation of Ultra High Molecular Weight (UHMW) DNA from a variety of solid tumors and tissue types.
  • The new kit was successfully validated on a wide variety of tumors and tissues (bladder, lung, liver, kidney, colon, breast, prostate,brain, thyroid,ovary, testes and uterus).
  • DNA isolated with the kit is of unprecedented length, resulting in isolation of molecules up to megabase lengths.
  • By making the DNA isolation simpler, faster, and less expensive, we enable the routine analysis of solid tumors.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies BELLUS Health (BLU) Investors of Ongoing Investigation of Possible Securities Fraud, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact the Firm

Thursday, July 9, 2020 - 11:01pm

The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims.

Key Points: 
  • The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims.
  • Hagens Berman also encourages persons who may be able to assist the Firms investigation to contact its attorneys.
  • Hagens Bermans proprietary investigation focuses on BELLUSs statements concerning the efficacy of its lead drug candidate, BLU-5937.
  • Were focused on investors losses and whether BELLUS misled investors about BLU-5937s viability, said Reed Kathrein, the Hagens Berman partner leading the investigation.